Loprodiol is tranquillizer and muscle relaxant.

KETOCAINOL is an antiarrhythmic agent, anaesthetic.

Fluspiperone, a butyrophenone derivative that was invented as an antipsychotic agent. However, information about the further development of this drug is not available.

Fluzoperine was studied as an antiarrhythmic agent. However, information about the current use of this drug is not available.

Fomidacillin (also known as BRL 36650) is a type of penicillin with antibacterial activity. Studies on volunteers have shown that the drug possessed the bactericidal activity and could be a candidate for the treatment of gram-negative bacillary infections. However, information about the further development of this drug is not available.

Fosmenic acid was used for the treatment of atherosclerosis. Information about the current use of this drug is not available.

Formebolone is an orally active anabolic-androgenic steroid that is included in the list of prohibited substances by the World Anti-Doping Agency. Formebolone was used in Italy and Spain for infants with malnutrition.

Fotretamine was developed as an immunosuppressant and antineoplastic agent. However, information about the further development of this drug is not available.

Fosmidomycin (3-(formylhydroxyamino)-propylphosphonic acid mono-sodium salt, 3-(N-formyl-N-hydroxyamino)-propylphosphonic acid mono-sodium salt, FR-31564) is a potent inhibitor of P. falciparum 1-deoxy-D-xylulose-5-phosphate reductoisomerase (PfDXR), developed by Albert Schweitzer Hospital for P. falciparum malaria treatment. Fosmidomycin was originally isolated as natural antibiotic from Streptomyces lavendulae. Fosmidomycin is active against a broad range of enterobacteria, but not against Gram-positive organisms or anaerobes. Fosmidomycin was developed as far as an early phase II study for the treatment of urinary tract infections by Fujisawa Pharmaceutical Company (Osaka, Japan) in the early eighties, but these trials have been discontinued. In recent clinical studies, it was shown that fosmidomycin is effective in curing uncomplicated Plasmodium falciparum malaria in humans. The treatment was well tolerated and resulted in a fast parasite and fever clearance. However, the high rate of recrudescence precludes the use of fosmidomycin as a monotherapy. In drug combination studies, the synergy of fosmidomycin with clindamycin was observed. Clinical studies with a fosmidomycin-clindamycin combination are currently ongoing.